Overall survival was longer and the rate of remission was higher among patients who received azacitidine (Vidaza) with venetoclax (Venclexta) than among those who received azacitidine alone in previously untreated patients who were ineligible for intense chemotherapy. Compared to the control group, the venetoclax-azacitidine group had a greater incidence of febrile neutropenia.